Sanofi Says Weak Decision-Making Hurt Pipeline, Promises More Disciplined R&D

Sanofi SA (NASDAQ: SNY ) on Thursday reported second-quarter sales of $13.482 billion (11.597 billion euros), beating the consensus of $12.65 billion. Sales increased 16% year over year, up 17.8% in constant currency. Dupixent Drives Growth While Vaccines Sales Decline Dupixent sales increased by 37.6% to 5.154 billion euros, above 5 billion euros per quarter for the first time. Global sales continued to be driven by strong volume growth across approved indications, and Dupixent retained a leading market position across its disease areas. Vaccines sales were 1.15 billion euros and decreased by 4.7%, mainly driven by lower sales of influenza and meningitis, travel, and endemic vaccines. Beyfortus sales were 108 million euros and increased by 54.2%, driven by Rest of World (+37.1%) benefiting from the expanded geographical availability and use in the Southern Hemisphere. The company rep...